ARTV vs NKTX
ARTV: Artiva Biotherapeutics develops allogeneic natural killer cell immunotherapies for cancer, with its lead candidate AlloNK advancing through clinical trials. NKTX: Nkarta is a clinical-stage biotech developing off-the-shelf, engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases through targeted B-cell depletion.
Side-by-side fundamentals
| Metric | ARTV | NKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $10.02 | $2.41 | |
| Market cap as of 2026-07-23 | $487M | $172M | |
| PEG as of 2026-07-23 | -0.15 | n/a | |
| Net margin as of 2026-07-23 | -26045.0% | -17566.7% | NKTX higher |
| Operating margin as of 2026-07-23 | -26805.6% | -19250.0% | NKTX higher |
| ROE as of 2026-07-23 | -60.2% | -30.9% | NKTX higher |
| ROA as of 2026-07-23 | -52.4% | -24.2% | NKTX higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.00 | NKTX lower |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-23 | 6.02 | 0.92 | |
| 1-year return as of 2026-07-22 close | +292.2% | +34.4% | ARTV higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.